Seperately Filed Delaying Amendment Under Securities Act Rule 473 to Delay Effectiveness of a 1933 Act Registration Statement (del Am)
August 01 2022 - 12:45PM
Edgar (US Regulatory)
August
1, 2022
VIA
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
DC 20549
Re: |
Qualigen
Therapeutics, Inc. |
|
Registration
Statement on Form S-3 (File No. 333-266430) |
Ladies
and Gentlemen:
Reference
is made to the Registration Statement on Form S-3 (File No. 333-266430) filed with the Securities and Exchange Commission (the “Commission”)
by Qualigen Therapeutics, Inc. on July 29, 2022 (the “Registration Statement”). Pursuant to Rule 473(c) of the Securities
Act of 1933, as amended (the “Act”), the following delaying amendment, prescribed by Rule 473(a) of the Act, is hereby incorporated
into the facing page of the Registration Statement:
“The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective
on such date as the Commission, acting pursuant to said section 8(a), may determine.”
No
fees are required in connection with this filing. If you have any questions or comments in connection with this delaying amendment, please
call Wendy Grasso, Reed Smith LLP, at 212-549-0216, outside counsel to the Company.
|
Qualigen
Therapeutics, Inc. |
|
|
|
|
By: |
/s/
Christopher L. Lotz |
|
Name: |
Christopher
L. Lotz |
|
Title: |
Chief
Financial Officer |
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Apr 2023 to Apr 2024